Sponsors (10)
The resolution seeks to accelerate glioblastoma research, collaboration, and public awareness to benefit patients and researchers, but does so at the cost of increased public spending, potential patient out-of-pocket expenses, and the risk of creating unrealistic near-term expectations.
Patients with glioblastoma could gain faster development and greater access to new therapies and clinical trials due to increased research funding, coordination, and emphasis on biomarker-driven studies.
Researchers and medical institutions would see improved multi-institutional collaboration and trial readiness from strengthened research infrastructure and biomarker testing emphasis.
Patients and their families could benefit from greater public awareness leading to earlier diagnosis and stronger caregiver support networks.
Some patients could face higher out-of-pocket costs if increased biomarker testing or related services are not covered by insurers.
Taxpayers may bear increased federal spending to support expanded research and clinical programs, potentially diverting funds from other priorities.
Patients and families might experience heightened expectations for near-term treatment breakthroughs that could be unmet given glioblastoma's historical resistance to rapid progress.
Based on analysis of 2 sections of legislative text.
Recognizes glioblastoma’s severe health and financial impacts, endorses research coordination and patient/caregiver engagement, and calls for greater public awareness.
Directs recognition of glioblastoma as a severe, often fatal brain cancer with poor survival, high out-of-pocket costs, limited approved treatments, and recent changes in diagnostic standards. Calls for greater public awareness, patient and caregiver involvement in research, and support for multi-institutional preclinical and early clinical efforts such as the National Cancer Institute’s Glioblastoma Therapeutics Network.
Introduced June 17, 2025 by Lindsey O. Graham · Last progress June 17, 2025